Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff
Replimune shares fall after FDA briefing documents questioned RP1 trial data for advanced melanoma ahead of a key advisory committee meeting.
Replimune's main medicine test results were too confusing for FDA experts to understand clearly. When people can't trust that important test numbers are clear and reliable, it makes them worried about whether the medicine really works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.